KALA BIO, Inc. (NASDAQ:KALA) Short Interest Up 28.0% in October

KALA BIO, Inc. (NASDAQ:KALA) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 37,500 shares, a growth of 28.0% from the October 15th total of 29,300 shares. Based on an average daily trading volume, of 17,600 shares, the days-to-cover ratio is presently 2.1 days. Currently, 1.0% of the company’s stock are sold short.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on KALA shares. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of KALA BIO in a research report on Friday. Oppenheimer reissued an “outperform” rating and set a $15.00 price target on shares of KALA BIO in a report on Monday, August 19th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP acquired a new position in shares of KALA BIO, Inc. (NASDAQ:KALA) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO comprises about 1.0% of SR One Capital Management LP’s holdings, making the stock its 9th biggest holding. SR One Capital Management LP owned approximately 15.76% of KALA BIO as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 24.61% of the company’s stock.

KALA BIO Price Performance

NASDAQ KALA opened at $6.70 on Friday. KALA BIO has a 52-week low of $4.21 and a 52-week high of $10.97. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.15 and a quick ratio of 3.07. The firm has a market capitalization of $30.89 million, a price-to-earnings ratio of -0.54 and a beta of -2.13. The company has a 50 day simple moving average of $6.02 and a 200-day simple moving average of $6.29.

KALA BIO (NASDAQ:KALA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.43) by $0.50. Equities research analysts predict that KALA BIO will post -11.76 earnings per share for the current fiscal year.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.